L-158-2022

Agreement ID
L-158-2022
Lead IC
NCI
Exclusivity
Nonexclusive
External Party
MilliporeSigma
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-3912     Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use